Skip to main content
Premium Trial:

Request an Annual Quote

Nasdaq Warns BG Medicine Again on Listing Requirement

NEW YORK (GenomeWeb News) – BG Medicine has been warned by Nasdaq that it fails to meet another requirement to remain listing on the Nasdaq Global Market, the company said in a document filed with the US Securities and Exchange Commission on Wednesday.

In a Nov. 22 letter from Nasdaq, BG Medicine was told that its publicly held shares closed below the minimum $15 million threshold for the preceding 30 consecutive business days, putting the company at risk of being delisted. BG Medicine has until May 21, 2014 to regain compliance.

The firm also is in danger of being listed from Nasdaq for failing to meet two other requirements. Earlier this month the exchange notified the company that it has not regained compliance with a listing requirement of at least $50 million in market value of its listed securities. BG Medicine has requested a hearing with a Nasdaq panel on the matter.

Additionally, BG Medicine is not in compliance with a listing requirement calling for a minimum $1 closing bid price on its stock. It has until March 24, 2014 to regain compliance with that rule.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.